A chronic inflammatory airway disorder, asthma is marked by airway hyperresponsiveness with recurrent episodes of wheezing, coughing, tightness of the chest, and shortness of breath. Typically, these episodes are associated with airflow obstruction that may be reversed spontaneously or with treatment.

Asthma affects approximately 300 million people around the world. In children, males have a higher asthma risk; in adults, females have a higher prevalence.

Experts believe asthma results from various host factors, environmental factors, or a combination. Host factors include gender, obesity, and genetics. Genetic factors include atopy. Defined as a genetic tendency to develop allergic diseases, such as asthma and allergic rhinitis, atopy commonly is linked to an immunoglobulin E (IgE)-mediated response to allergens.

Pathophysiology
Understanding asthma pathophysiology helps you understand how the condition is diagnosed and treated. Our knowledge of asthma pathogenesis has changed dramatically in the last 25 years, as researchers have found various asthma phenotypes.

Asthma involves many pathophysiologic factors, including bronchiolar inflammation with airway constriction and resistance that manifests as episodes of coughing, shortness of breath, and wheezing. Asthma can affect the trachea, bronchi, and bronchioles. Inflammation can exist even though obvious signs and symptoms of asthma may not always occur.

Bronchospasms, edema, excessive mucus, and epithelial and muscle damage can lead to bronchoconstriction with bronchospasm. Defined as sharp contractions of bronchial smooth muscle, bronchospasm causes the airways to narrow; edema from microvascular leakage contributes to airway narrowing. Airway capillaries may dilate and leak, increasing secretions, which in turn causes edema and impairs mucus clearance. (See How bronchospasm constricts the airway.)

Asthma also may lead to an increase in mucus-secreting cells with expansion of mucus-secreting glands. Increased mucus secretion can cause thick mucus plugs that block the airway. Injury to the epithelium may cause epithelial peeling, which may result in extreme airway impairment. Loss of the
Asthma also causes loss of enzymes that normally break down inflammatory mediators, with ensuing reflexive neural effects from sensory nerve exposure. Without proper treatment and control, asthma may cause airway remodeling leading to changes to cells and tissues in the lower respiratory tract; these changes cause permanent fibrotic damage. Such remodeling may be irreversible, resulting in progressive loss of lung function and decreased response to therapy.

Classifying asthma
Asthma may be atopic, nonatopic, or a combination.
• Atopic asthma begins in childhood and is linked to triggers that initiate wheezing. It may arise after exposure and response to a specific allergen, such as dust mites, grass or tree pollen, pet dander, smoke, or certain drugs or foods. On exposure to a trigger, excessive release of IgE occurs, which initiates B-lymphocyte activation. IgE binds to cells related to inflammation. This action causes release of inflammatory mediators (such as chemokines, nitric oxide, prostaglandin D2, cytokines, histamine, and leukotrienes), in turn triggering airway inflammation and bronchoconstriction. Women who smoke during pregnancy may predispose their unborn children to higher IgE levels, causing hyperresponsiveness and asthma development. Exposure to pollution may have the same effect.
• Nonatopic asthma doesn’t involve an IgE response. It may have fewer obvious triggers and usually occurs in adults, possibly secondary to a viral infection.

Diagnosis
Asthma diagnosis goes beyond symptoms, such as coughing, chest tightness, wheezing, and dyspnea—and even beyond signs and symptoms that worsen at night and improve after treatment. Diagnosis may require pulmonary function tests (PFTs) and peak expiratory flow (PEF) measurements. With asthma, the ratio of forced expiratory volume in 1 second (FEV₁) to forced vital capacity (FVC, also called FEV₁%) typically declines.

Asthma symptoms can be reversed by a rapid-acting beta₂-agonist, such as albuterol, as measured by spirometry. The generally acceptable response to beta₂-agonists is a 12% or 200-mL increase in FEV₁ or FVC. PEF measurements not only aid diagnosis but also help clinicians monitor the disease.

Some patients with asthma signs and symptoms may have normal PFT results. They may need further diagnostic testing, such as airway response testing using a bronchial challenge. (See Bronchial challenge.)

Clinicians must rule out other conditions that may decrease FEV₁ and cause signs and symptoms that mimic asthma. These conditions include vocal cord dysfunction, gastroesophageal reflux disease, ischemic cardiac pain, chronic obstructive pulmonary disease, heart failure, upper-airway obstruction, cystic fibrosis, hyperventilation, and foreign-body aspiration. Viral respiratory infections may lead to asthma exacerbations or contribute to eventual development of the disorder.

Management
Asthma management involves both acute and long-term treatment. Medication selection hinges on the
patient’s age, disease severity, and comorbidities.

Be sure to obtain a complete medication history before the patient starts taking asthma medications. Some drugs, including beta-blockers, angiotensin-converting enzyme inhibitors, cholinergics, and nonpotassium-sparing diuretics, may be contraindicated for patients receiving certain asthma agents.

**Rescue (quick-relief) drugs**

Meant for short-term symptom relief, rescue drugs cause bronchodilation and are used mainly to prevent or treat an asthma attack. They begin working within minutes and may remain effective for up to 6 hours. Potential side effects include jitteriness and palpitations. Rescue drugs include ipratropium bromide inhaler (Atrovent), short-acting beta₂-agonists, and oral corticosteroids.

- Ipratropium bromide, an anticholinergic, may be given in combination with short-acting beta₂-agonists in some cases.
- Beta₂-agonists used for quick relief include albuterol, levalbuterol, metaproterenol, and terbutaline.
- Oral corticosteroids, such as prednisone and methylprednisolone, sometimes are used for brief periods during acute asthma attacks that don’t respond to usual treatments. Long-term use can lead to high blood pressure, muscle weakness, cataracts, osteoporosis, decreased ability to resist infection, and reduced growth in children.

**Long-term control agents**

Used to prevent asthma attacks and control chronic symptoms, these agents include inhaled corticosteroids, leukotriene modifiers, long-acting beta-agonists (LABAs), theophylline, and combination inhalers that contain both a corticosteroid and an LABA. These drugs may take days or weeks to reach maximal effect.

Leukotriene modifiers help prevent symptoms for up to 24 hours. LABAs, which may last up to 12 hours, usually are given in combination with an inhaled corticosteroid, because when used alone they may lead to a severe asthma attack. LABAs also are prescribed to prevent nocturnal asthma symptoms, such as coughing. Theophylline, given orally, acts as a bronchodilator and also is used to treat nocturnal symptoms.

**Patient education**

Patient education is crucial in asthma management. Teach patients and their families how to use a peak flow meter, optimize environmental controls, and recognize asthma signs and symptoms. Stress the importance of smoking cessation. Urge patients to receive annual vaccinations, as asthma increases the risk of complications from respiratory diseases, such as pneumonia and influenza.

**Selected references**

Asthma overview. American Academy of Allergy Asthma and Immunology. www.aaaai.org/conditions-and-treatments/asthma.aspx


Shari J. Lynn and Kathryn Kusho-Reese are instructors at the Johns Hopkins University School of Nursing in Baltimore, Maryland.

---

**Bronchial challenge**

In the bronchial challenge, a patient with airway hypersensitivity inhales an aggravating agent with the potential to cause bronchoconstriction. The inhaled agent may act directly (such as inhaled histamine or methacholine) or indirectly (such as mannitol).

The agent’s histamine properties increase mucus production and bronchoconstriction. Cholinergic properties of methacholine cause wheezing and shortness of breath. The mannitol inhalation challenge (approved in some countries) may cause airway narrowing in asthmatic patients by altering the osmolarity of airway surface liquid, in turn resulting in mast cell granulation and release of inflammatory mediators.

In these tests, a decrease of 15% to 20% from the patient’s baseline forced expiratory volume in 1 second indicates asthma.